Document is current
Any future updates will be listed below
-
Authors
Tran, Maylis https://orcid.org/0009-0006-8150-9512
Poulet, Pierre-Emmanuel
Petit, Emilien
Durr, Alexandra
Klockgether, Thomas
Ashizawa, Tetsuo
Coarelli, Giulia
du Montcel, Sophie Tezenas
-
Funding
Funding for this research was provided by:
French Ministry of Health
National Institute of Neurological Disorders and Stroke (U01 NS104326)
National Institute of Health (NIH RC1 NS068897)
Agence Nationale de la Recherche (ANR) - Investissements d'avenir (ANR-10-IAIHU-06)
- License Information
-
More Information
Article History
Received: 25 February 2025
Accepted: 20 February 2026
First Online: 5 March 2026
Declarations
:
: Not applicable.
: Not applicable.
: Dr. Tezenas du Montcel receives research support from Biogen and Vico Therapeutics. Dr. Ashizawa received grants from NAF and Biogen and participates in Biohaven clinical trials NCT03952806 and NCT03701399. Dr. Durr declares that her institution (Paris Brain Institute) receives consulting or compensation fees on her behalf from Biogen, Huntix, UCB, Wavelife Therapeutics, PTC Therapeutics, Vico, as well as research grants from the NIH, ANR, Brain-team and the National Hospital Clinical Research Program, and she holds partly a patent B 06291873.5 on “Anaplerotic therapy of Huntington’s disease and other polyglutamine diseases.”
